BioHarvest Sciences Inc. (BHST) Income Statement
BHST 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBHST revenue and net income
Where BHST's revenue goes
2025Each bar shows an amount and its share of revenue. BHST kept −32.3% of revenue as net income.
BHST profit margins
BHST growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +37.0% | +84.5% | +144.4% | — |
| Gross profit | +46.9% | +156.1% | +171.8% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BHST quarterly EPS vs estimates
BioHarvest Sciences beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 12, 2026 (estimate $-0.16).
BHST income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $34.5M | $25.2M | $12.7M | $5.5M | $2.1M | $396,000 | $218,000 | $0 | $0 | $0 |
| Cost of revenue | $14.0M | $11.2M | $7.0M | $4.3M | $1.4M | $258,000 | $189,000 | — | $501 | $502 |
| Gross profit | $20.5M | $13.9M | $5.6M | $1.2M | $670,000 | $138,000 | $29,000 | — | −$501 | −$501 |
| Research & development | $5.3M | $4.8M | $3.4M | $2.3M | $4.1M | $1.3M | $1.3M | — | — | — |
| Sales, general & admin | $19.1M | $14.7M | $12.1M | $9.4M | $4.8M | $4.3M | $920,000 | $121,031 | $55,156 | $126,935 |
| Total operating expenses | $26.1M | $20.9M | $15.6M | $11.8M | $9.2M | $6.3M | $2.3M | $5,000 | $93,703 | $127,461 |
| Operating income | −$5.6M | −$7.0M | −$10.0M | −$10.6M | −$8.5M | −$6.2M | −$2.3M | −$5,000 | −$96,641 | −$121,673 |
| Interest income | $54,000 | $0 | — | — | $0 | $131,000 | — | — | — | — |
| Interest expense | $2.7M | $1.9M | $2.0M | $1.4M | $805,000 | $535,888 | $2.2M | $3,951 | $6,772 | $2,153 |
| Income before taxes | −$11.1M | −$12.9M | −$12.6M | −$11.2M | −$9.8M | −$6.6M | −$5.3M | −$5,000 | −$103,413 | −$123,724 |
| Income taxes | $76,000 | $8,000 | — | — | — | — | — | — | — | — |
| Net income | −$11.1M | −$12.9M | −$12.6M | −$11.2M | −$9.8M | −$6.6M | −$5.3M | −$5,000 | −$103,413 | −$123,724 |
| EBITDA | −$6.7M | −$9.7M | −$9.8M | −$9.1M | −$8.6M | −$5.8M | −$2.0M | −$159,630 | −$93,219 | −$126,935 |
| EPS (diluted) | −$0.61 | −$0.85 | −$0.93 | −$0.86 | −$0.80 | −$0.64 | −$1.75 | −$0.01 | −$0.24 | −$0.30 |
| Gross margin | 59.3% | 55.4% | 44.5% | 22.2% | 31.9% | 34.8% | 13.3% | — | — | — |
| Operating margin | −16.2% | −27.7% | −78.6% | −193.0% | −403.9% | −1,557.1% | −1,059.6% | — | — | — |
| Net margin | −32.3% | −51.3% | −99.1% | −204.4% | −467.5% | −1,662.6% | −2,435.8% | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.8M | $8.5M | $9.1M | $9.1M | $8.5M | $7.9M | $7.3M | $6.5M | $6.0M | $5.3M | $4.5M | $3.2M |
| Cost of revenue | $3.8M | $3.5M | $3.8M | $3.5M | $3.4M | $3.3M | $3.2M | $2.8M | $2.9M | $2.3M | $2.2M | $1.8M |
| Gross profit | $5.1M | $5.0M | $5.2M | $5.6M | $5.1M | $4.6M | $4.1M | $3.7M | $3.1M | $3.0M | $2.3M | $1.4M |
| Research & development | $1.7M | $1.4M | $1.3M | $1.4M | $1.3M | $1.2M | $1.4M | $1.3M | $1.1M | $1.0M | $1.1M | $894,000 |
| Sales, general & admin | $5.9M | $5.5M | $3.5M | $5.1M | $5.6M | $5.1M | $4.0M | $4.5M | $3.8M | $3.4M | $3.6M | $2.6M |
| Total operating expenses | $7.6M | $6.9M | $6.3M | $6.5M | $6.9M | $6.3M | $5.8M | $5.8M | $4.9M | $4.4M | $4.8M | $3.4M |
| Operating income | −$2.5M | −$1.8M | −$1.1M | −$920,000 | −$1.8M | −$1.7M | −$1.7M | −$2.1M | −$1.8M | −$1.4M | −$2.5M | −$2.0M |
| Interest income | $97,000 | $114,000 | — | — | $0 | $0 | — | $0 | $1.5M | $0 | — | $435,000 |
| Interest expense | $1.3M | $875,000 | $1.6M | $1.5M | $2.2M | $579,244 | $1.3M | $587,000 | $378,000 | $5.2M | $2.2M | $155,000 |
| Income before taxes | −$3.7M | −$2.6M | −$2.3M | −$2.5M | −$4.0M | −$2.3M | −$2.9M | −$2.7M | −$687,000 | −$6.6M | −$7.2M | −$1.7M |
| Income taxes | $52,000 | $46,000 | −$64,000 | $63,000 | $39,000 | $38,000 | $8,000 | — | — | — | — | — |
| Net income | −$3.7M | −$2.6M | −$2.2M | −$2.5M | −$4.1M | −$2.3M | −$3.0M | −$2.7M | −$687,000 | −$6.6M | −$7.2M | −$1.7M |
| EBITDA | −$2.0M | −$1.3M | −$3.4M | −$535,000 | −$1.4M | −$1.3M | −$2.5M | −$1.8M | $47,990 | −$1.2M | −$5.5M | −$1.4M |
| EPS (diluted) | −$0.17 | −$0.11 | −$0.10 | −$0.14 | −$0.24 | −$0.13 | −$0.17 | −$0.16 | −$0.04 | −$0.48 | −$0.53 | −$0.13 |
| Gross margin | 57.5% | 59.2% | 57.6% | 61.4% | 59.7% | 58.5% | 56.7% | 56.8% | 51.5% | 56.2% | 50.7% | 44.5% |
| Operating margin | −28.4% | −21.6% | −12.4% | −10.1% | −21.3% | −21.9% | −23.2% | −32.1% | −29.5% | −26.6% | −56.4% | −62.0% |
| Net margin | −42.0% | −31.0% | −24.3% | −27.7% | −47.9% | −29.7% | −40.6% | −41.1% | −11.4% | −123.1% | −160.1% | −53.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BHST's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BHST financial results
In fiscal year 2025 (ended December 31, 2025), BioHarvest Sciences reported revenue of $34.5 million, up 37.0% from the year before. It had a net loss of $11.1 million, a net profit margin of −32.3%. Diluted earnings per share came to −$0.61. Over five years revenue grew at an average rate of 144.4% a year.
See the BHST stock overview for the latest quote and news, or the BHST chart for price history and technical indicators.
BHST income statement FAQ
What is BioHarvest Sciences's annual revenue?
BioHarvest Sciences reported total revenue of $34.5 million for fiscal year 2025, which ended on December 31, 2025. That was up 37.0% from $25.2 million the previous year.
Is BioHarvest Sciences profitable?
No. BioHarvest Sciences reported a net loss of $11.1 million in fiscal 2025, a net profit margin of −32.3%; its operating margin was −16.2%.
What is BioHarvest Sciences's gross margin?
BioHarvest Sciences's gross margin was 59.3% in fiscal 2025: for every $100 of revenue, BioHarvest Sciences kept $59 after the direct cost of its products and services.
How much does BioHarvest Sciences spend on research and development?
BioHarvest Sciences spent $5.3 million on research and development in fiscal 2025, 15.4% of revenue.
How fast is BioHarvest Sciences growing?
Revenue grew 144.4% a year on average over the last five fiscal years, from $0.4 million to $34.5 million.
What are BioHarvest Sciences's earnings per share?
BioHarvest Sciences earned $-0.61 per diluted share in fiscal 2025, compared with $-0.85 a year earlier.
When will BioHarvest Sciences report its next earnings?
BioHarvest Sciences is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens.
When does BioHarvest Sciences's fiscal year end?
BioHarvest Sciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.